CGON
CG Oncology, Inc. Common stockNASDAQHealthcare$67.48+1.03%ClosedMarket Cap: $5.70B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
6.94
P/S
1411.78
EV/EBITDA
-33.94
DCF Value
$-2.20
FCF Yield
-2.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
-15.0%
Operating Margin
-4722.1%
Net Margin
-3985.0%
ROE
-22.9%
ROA
-20.3%
ROIC
-25.0%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $2.3M | -25.5% | $-48.7M | $-41.3M | $-0.52 | — |
| FY 2025 | $4.0M | -15.0% | $-190.8M | $-161.0M | $-2.08 | — |
| Q3 2025 | $1.7M | 5.3% | $-51.1M | $-43.8M | $-0.57 | — |
| Q2 2025 | $0.00 | -Infinity% | $-48.7M | $-41.4M | $-0.54 | — |
| Q1 2025 | $52.0K | 100.0% | $-42.2M | $-34.5M | $-0.45 | — |
| Q4 2024 | $456.0K | 100.0% | $-38.0M | $-31.8M | $-0.49 | — |
| FY 2024 | $1.1M | 100.0% | $-114.7M | $-88.0M | $-1.41 | — |
| Q3 2024 | $43.0K | 100.0% | $-28.3M | $-20.4M | $-0.30 | — |
| Q2 2024 | $111.0K | 100.0% | $-25.9M | $-18.9M | $-0.28 | — |
| Q1 2024 | $529.0K | 99.2% | $-22.5M | $-16.9M | $-0.22 | — |
| Q4 2023 | $1.0K | -300.0% | $-18.9M | $-16.1M | $-0.33 | — |
| FY 2023 | $204.0K | 100.0% | $-55.4M | $-48.6M | $-1.02 | — |